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LETTER TO THE EDITOR
Steps Towards Developing a Cure for Autoimmunity
Tamara Zemlo
The Science Advisory Board, 2111 Wilson Boulevard, Suite 250, Arlington, VA 22201, USA
Research into the molecular and cellular underpin-
nings of autoimmunity advances our understanding of
immunefunctionsandtheroleinﬂammationplaysinme-
diating many of the symptoms of the multitude of au-
toimmune diseases. This knowledge serves as the foun-
dation for identifying potential targets for treatment and
developing novel therapies to prevent, modulate, and ul-
timately cure autoimmune diseases. The Science Advisory
Board, in conjunction with BioInformatics, LLC (Arling-
ton, Va), has interviewed hundreds of immunologists re-
gardingthenatureoftheirresearchandthescientiﬁcchal-
lenges they face in autoimmune disease research. High-
lights from this benchmarking study are presented below
in the context of promising research opportunities.
Removingthebarriers
Hindered by technology barriers, research bottle-
necks,andﬁnancialandtimeconstraints,fewpharmaceu-
ticalcompanieshavesuccessfullyproducednewtherapeu-
tics for autoimmune diseases in recent years. Improving
this drug discovery process begins by ﬁrst developing the
underlying technologies that facilitate basic research sci-
ence. Improved culturing techniques are needed to prop-
agate human cells in the laboratory so that researchers
may study how cells from diseased patients diﬀer from
cells from healthy individuals. Secondly, the discovery of
new targets for autoimmune diseases is often complicated
by the heterogeneity of autoimmune diseases. One way
around this problem may be to focus on obtaining a more
complete understanding of the genetics of autoimmune
diseases, which scientists have identiﬁed as an immediate
priority.
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Once genes have been linked to speciﬁc autoimmune
diseases, they can be categorized into groups based on
their role in disease onset and progression. Genes that are
associated with multiple diseases would make the most
desirable targets for future therapeutics. Finally, the drug
discovery and development process is often hampered by
ﬁnancial and time constraints. By forming collaborations
with outside researchers, pharmaceutical and biotechno-
logical companies gain access to cutting-edge research
without spending the time and resources needed to cre-
ate specialized, autoimmunity R & D programs in-house.
The results of this research can serve as a sturdy founda-
tion that supports industry’s future drug discovery eﬀorts
dedicated to inventing novel autoimmune therapies.
Harnessingthepowerofgenetics
The majority of immunologists interviewed assert
that the research breakthrough that has the best hope
of leading to eﬀective treatments for autoimmune dis-
eases is the identiﬁcation of genes whose altered activ-
ity might contribute to autoimmunity. Furthermore, en-
hancing these correlations with population studies that
reveal polymorphisms and linking these genes with a
predisposition to a particular disease or constellation of
symptoms will be necessary in order to develop new ther-
apies and treatments within the next decade.
As scientists strive to uncover critical genetic linkages,
they continue to develop a greater understanding of the
molecular basis of these diseases. Despite this increasing
comprehension, research eﬀorts to date have been broad
and involve numerous approaches because autoimmune
diseasesencompassadiversesetofmolecularcomponents
and clinical events. However, recent advances in molecu-
lar biology techniques have enabled the discovery of spe-
ciﬁc autoantigens implicated in a variety of autoimmune
disorders. Knowledge of the molecular pathways control-
ling the production of these autoantigens has enabled the
pharmaceutical and biotechnology industry to focus on
the triggers and target molecules involved in causing au-
toimmunity.
With the ability to pinpoint genetic defects contribut-
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is being placed on genetic therapy, especially an ex vivo
approach. Antigen-speciﬁc CD4+ T cells and antigen-
presenting dendritic cells are critical mediators in the
pathogenesis of autoimmune diseases and are proving to
be ideal candidates for adoptive cellular gene therapy.
Thequesttocontrolcellsignaling
Notwithstanding the excitement surrounding genetic
therapies, most researchers interviewed indicated that cell
signaling regulators hold the most promise for treating
autoimmune diseases within the next decade. In an at-
tempt to ﬁnd new regulators of the immune system, re-
searchers are utilizing functional genome-wide screens,
which allows for the functional cloning of regulators in-
volved in multiple signal transduction pathways. A main
attraction of this strategy for the pharmaceutical and
biotechnology industry is that it requires no prior se-
quence information; and it does not skew the search to
previously known signaling molecules. The absence of
thesetechnicallimitationsopensupthepossibilityfordis-
covering many novel targets to control the immune sys-
tem through cell signaling pathways.
Strategiesfortoleranceinduction
Ideally it would be most eﬀective to prevent the loss
of immunological tolerance instead of trying to arrest
the progress of autoimmunity. However, identifying those
individuals who are at risk for a wide range of au-
toimmune diseases is a daunting epidemiologic prospect.
While some researchers are concentrating on this chal-
lenge, treatment breakthroughs for those individuals who
already have an autoimmune disease have evolved from
interventions based upon immunosuppression of those
built upon immunomodulation.
By devoting their R & D eﬀorts to reﬁning the
mechanism of immunomodulation, pharmaceutical and
biotechnology companies will be able to devise even more
eﬀective therapies. There is increasing interest in the use
of stem cell therapeutics to accomplish this goal. The ma-
jority of scientists questioned, however, believe that char-
acterizing the mechanism of tolerance breakdown con-
tributed by CD4+CD25+ regulatory T cells in association
with NKT cells will most aid in the advancement of au-
toimmune disease research.
Proﬁlingfutureprogress
The pharmaceutical and biotechnology industry
should place a continued emphasis on identifying puta-
tive autoantigens by applying more and more sophisti-
cated functional genomics techniques. Knowledge gained
from these experiments will likely be used to delve deeper
into the genetic, environmental, and infectious causes of
certain autoimmune diseases. This focus will include ef-
forts to explain the gender diﬀerences that are observed in
susceptibility to autoimmune diseases including, but are
not limited to, hormonal diﬀerences.
Further into the future, a variety of genetic therapy
approaches will become increasingly vital in treating au-
toimmunediseasesthroughthetransferofgenesencoding
for immunomodulatory cytokines or antigens that would
induce tolerization. Emphasis should thus be placed on
better understanding the heterogeneity of autoimmune
diseases in order to simplify the search for these common
pathway targets.
Although progress in autoimmunity typically occurs
by building upon a solid body of research, scientists must
learn to adapt and modify their objectives to incorporate
innovative hypotheses.Whetherornotnewresearchﬁnd-
ingsresultinamajorparadigmshiftinourunderstanding
of the fundamental causes of autoimmunity, they do rein-
force the certainty that it is only by basing strategic R & D
plans on basic research insights that substantial progress
can be made in developing the next generation of tools
that will enable the discovery of valuable therapeutics—
and even a cure for autoimmune diseases.
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